Infliximab-Dyyb

INFLECTRA, ZYMFENTRA

Tumor Necrosis Factor Blocker

NADAC/unit N/A

No Shortage Tier 1: 4.9% PA Req: 13.4%

Infliximab-Dyyb suppresses inflammation by blocking tumor necrosis factor, used in autoimmune conditions.

Covered Lives

Market Intelligence

2025-02-05 Class II Recall: McKesson

Explore in the Ecosystem

rxsaver.aiCompare prices for Infliximab-Dyyb drfinder.aiFind doctors who prescribe Infliximab-Dyyb rxbenefits.aiEmployer cost impact analysis clinicalrx.aiClinical profile: Infliximab-Dyyb

Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.